Kymera Therapeutics
KYMR
trading on NASDAQ
since 2020
$69.72
(Δ 0%)
+$0.00 since open
Kymera Therapeutics specializes in developing gene-editing therapies using Cas9 variants to target disease-causing genes for treatments in areas such as blood disorders, inflammatory diseases, and cancer.
| type | open | high | low |
market cap |
volume |
|---|---|---|---|---|---|
| stock | $44.95 | $49.34 | $43.12 | $1.83B | 3.52M |
| eps | p/e | p/s |
operating margin |
profit margin |
yield |
| -$0.82 | n/a | 252.84 | -336.77% | -296.75% | 0% |